| Dustyn Erik Williams, | |
|
2111 Kramer Ln Ste 100, Austin, TX 78758-4032 | |
| (512) 508-8320 | |
| (512) 488-1745 |
| Full Name | Dustyn Erik Williams |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 13 Years |
| Location | 2111 Kramer Ln Ste 100, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699064766 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | R3247 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dose Management Pa | 0648692673 | 2 |
News Archive
A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.
The use of technology in medicine takes another step forward with a program being road-tested now at Creighton University Medical Center.
A study of more than a half-million people in India who were exposed to the novel coronavirus SARS-CoV-2, or COVID-19, suggests that the virus' continued spread is driven by only a small percentage of those who become infected.
Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.
The United States Food and Drugs Administration (FDA) has approved Zelboraf (vemurafenib), a drug for the treatment of adults with a are type of blood cancer called Erdheim-Chester Disease or ECD.
› Verified 9 days ago
| Entity Name | Dose Management Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447874334 PECOS PAC ID: 0648692673 Enrollment ID: O20200622001162 |
News Archive
A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.
The use of technology in medicine takes another step forward with a program being road-tested now at Creighton University Medical Center.
A study of more than a half-million people in India who were exposed to the novel coronavirus SARS-CoV-2, or COVID-19, suggests that the virus' continued spread is driven by only a small percentage of those who become infected.
Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.
The United States Food and Drugs Administration (FDA) has approved Zelboraf (vemurafenib), a drug for the treatment of adults with a are type of blood cancer called Erdheim-Chester Disease or ECD.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dustyn Erik Williams, 2111 Kramer Ln Ste 100, Austin, TX 78758-4032 Ph: (512) 566-4233 | Dustyn Erik Williams, 2111 Kramer Ln Ste 100, Austin, TX 78758-4032 Ph: (512) 508-8320 |
News Archive
A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.
The use of technology in medicine takes another step forward with a program being road-tested now at Creighton University Medical Center.
A study of more than a half-million people in India who were exposed to the novel coronavirus SARS-CoV-2, or COVID-19, suggests that the virus' continued spread is driven by only a small percentage of those who become infected.
Forest Laboratories, Inc. today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent originally developed by Procter & Gamble Pharmaceuticals.
The United States Food and Drugs Administration (FDA) has approved Zelboraf (vemurafenib), a drug for the treatment of adults with a are type of blood cancer called Erdheim-Chester Disease or ECD.
› Verified 9 days ago
Dr. Tatiana B. Jacobson, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Caves Rd. Bldg C Ste. 102, Austin, TX 78746 Phone: 512-323-5465 Fax: 512-327-1390 | |
Preeti Venkatraman, M.B.B.S. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 601 E 15th St, Austin, TX 78701 Phone: 512-324-7000 | |
Pritesh Harish Gandhi, M.D., M.P.H. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1101 Camino La Costa, Austin, TX 78752 Phone: 512-684-1832 | |
Dr. Joshua Lane Davis, D.O. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1004 W 32nd St Unit 300, Austin, TX 78705 Phone: 512-324-3440 | |
Dr. Analicia Alvarado, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1500 Red River St, Austin, TX 78701 Phone: 512-324-7000 | |
Dr. Grace Marie Grant-jennings, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 7000 North Mopac, Suite # 420, Austin, TX 78731 Phone: 512-482-0045 Fax: 512-476-9892 | |
Dr. Debra Ann Patt, MD, MPH Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 6204 Balcones Dr, Austin, TX 78731 Phone: 512-427-9400 Fax: 512-342-2723 |